Series B Growth Epitel recently completed a $26M Series B financing to expand commercialization of its REMI Remote EEG Monitoring System, signaling aggressive growth and a need for scalable sales partnerships, channel development, and hospital/system integrator engagement.
Board and Exec With a new CFO and a strengthened Board leadership as of October 2026, Epitel is likely to pursue larger contracts and more complex procurement processes, creating opportunities for enterprise sales, budgeting, and compliance-focused discussions with finance and governance teams.
Strategic Partnerships Partnerships like Stratus expanding nationwide EEG access indicate appetite for OEM/co-sell arrangements and referenceable deployments; target similar electrophysiology, neurology clinics, and managed care networks to broaden adoption.
Public Funding Tie‑ins Past involvement in government grant funding from HHS suggests opportunities to align Epitel solutions with public health initiatives, federal/state grant programs, and value-based care pilots that require remote monitoring capabilities.
Clinical Footprint Recent FDA 510(k) clearances across wireless EEG monitoring and AI-driven tech, combined with Utah and broader US expansion, point to targeting regional health systems, academic medical centers, and epilepsy programs seeking scalable remote monitoring with AI insights.